Yorkville Advisors Global’s Apimeds Pharmaceuticals US APUS Stock Holding History

Yorkville Advisors Global’s Portfolio APUS Stock Details APUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25,000	Closed	-$440K	–	44
2025 Q2	$440K	Buy	+25,000	New	+$451K	0.13%	9

Other funds holding APUS

HTHT

Hemenway Trust Hemenway Trust Salem, New Hampshire $1.43B AUM 37.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Yorkville Advisors Global's APUS Position: Q3 2025 in Review

Yorkville Advisors Global sold out of Apimeds Pharmaceuticals US (APUS) in Q3 2025, closing a stake of 25,000 shares — an estimated $440K sold.

Yorkville Advisors Global first reported a position in APUS in Q2 2025 and held it in 1 quarter. The position peaked at $440K in Q2 2025. 8 funds tracked by Wall St. Rank hold APUS as of Q3 2025.

Yorkville Advisors Global reported no remaining Apimeds Pharmaceuticals US position as of Q3 2025 after selling out during the quarter.
Yorkville Advisors Global sold 25,000 Apimeds Pharmaceuticals US shares in Q3 2025, an estimated $440K.
Yorkville Advisors Global first reported a position in Apimeds Pharmaceuticals US in Q2 2025 and held it in 1 quarter.
Yorkville Advisors Global's Apimeds Pharmaceuticals US position peaked at $440K in Q2 2025.
8 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q3 2025.

Based on Yorkville Advisors Global's 13F filing for Q3 2025, filed 18 Nov 2025.